UNLV
$NVCT Once promised 2026 data readouts for NXP900 1b mono and resistance combo therapies now 1H 2027. Insiders not selling and my PT. Deprioritizing assets understandable for asset rich small biotech. NXP100 will be muti billion blockbuster by itself for this 600M market cap. GLSI another small biotech stock I'm very deep
3

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Farticles%2Fmain%2F08%2F595.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault18.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault12.jpg)